Equity Long-Short

Mo Aziz

Capital markets veteran with 25 years across sell-side and buy-side research, investor relations, and fund management. Currently publish independent equity research (Mofferies Investment Research, via Smartkarma) spanning semiconductor memory (DRAM/NAND/HBM), foundry, semiconductor equipment and advanced packaging, gold and cross-asset strategy, financials forensics, and APAC IPOs — with a standing watchlist of 190+ companies across 41 countries. Background includes deep aviation-sector expertise (airlines, airports, OEMs, lessors, air cargo, travel/OTAs). Approach centers on identifying cyclical inflection points and mispriced risk across sectors, translated into explicit, actionable calls.

Chroma ATE (2360 TT): Initiation — Silent Gatekeeper of the Electrification Supercycle

TechChain Insights Q&A: AI Chips Cannot Ship Until Chroma's Machines Pass Them

TechChain Insights Management Q&A: Topco Scientific Sells the Picks & Shovels Chip Fabs Use Up

Equity Bottom-Up

<ul>
<li>Advantest is a critical AI gatekeeper, validating every HBM die before shipment. Its &gt;50% market share, long qualification cycles, and high switching costs underpin visibility into AI-driven demand through 2027–2028.</li>
<li>Exceptional, increasingly non-cyclical financials with multi-year visibility. FY25 revenue rose 45%, operating margin reached 44%, ROE 58%, and FCF ¥300bn, while FY26 guidance implies another 25% EPS growth.</li>
<li>We value Advantest as semiconductor infrastructure rather than a cyclical, reflecting its visible earnings outlook. HOLD with ¥34,050 target price; limited upside warrants waiting for a more attractive entry point.</li>
</ul>


Advantest is a critical AI gatekeeper, validating every HBM die before shipment. Its &gt;50% market share, long qualification cycles, and high switching costs underpin visibility into AI-driven demand through 2027–2028.
Exceptional, increasingly non-cyclical financials with multi-year visibility. FY25 revenue rose 45%, operating margin reached 44%, ROE 58%, and FCF ¥300bn, while FY26 guidance implies another 25% EPS growth.
We value Advantest as semiconductor infrastructure rather than a cyclical, reflecting its visible earnings outlook. HOLD with ¥34,050 target price; limited upside warrants waiting for a more attractive entry point.


Advantest Corporation (6857 JP): The Invisible Toll Booth On The AI Superhighway